Author

P. Waring

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Llop-Guevara· 1 shared A. R. Delbridge· 1 shared A. Strasser· 1 shared A. Wilkinson· 1 shared A. Yong· 1 shared C. E. Caldon· 1 shared C. Lee· 1 shared C. M. Sergio· 1 shared

Activity by Year

2017-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Llop-Guevara

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BCL-XL is essential for the protection from secondary anemia caused by radiation-induced fatal kidney damage

K. Brinkmann, P. Waring, S. Glaser, V. Wimmer, D. Nhu, L. Whitehead, A. R. Delbridge, G. Lessene, M. Herold, G. L. Kelly, S. Grabow, A. Strasser

The paper shows that BCL-XL protects adult kidneys from radiation-induced damage, leading to secondary anemia, and highlights its importance in cancer therapy combinations.

bioRxiv · Apr 28, 2020 · PreprintPharmacology & Toxicology

Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors

D. Aziz, N. Portman, K. Fernandez, C. Lee, S. Alexandrou, A. Llop-Guevara, A. Yong, A. Wilkinson, C. M. Sergio, D. Ferraro, D. Etemadmoghadam, D. Bowtell, k. Investigators, V. Serra, P. Waring, , C. E. Caldon

The paper identifies cyclin E1 stabilization in BRCA1-mutated breast cancers and shows synergy between CDK2 and PARP inhibitors in treating these cancers.

bioRxiv · Jan 29, 2020Cancer Biology

PI3K Activation In Neural Stem Cells Drives Tumorigenesis Which Can Be Suppressed By Targeting CREB

P. Daniel, G. Filiz, D. Brown, M. Christie, P. Waring, Y. Zhang, J. Haynes, C. Pouton, D. Flanagan, E. Vincan, T. Johns, K. Montgomery, W. Phillips, T. Mantamadiotis

This study shows that PI3K pathway activation in neural stem cells initiates tumorigenesis, and targeting CREB reduces tumor growth in a mouse model of high-grade glioma.

bioRxiv · May 30, 2017Cancer Biology